Grand Hopital De Charleroi
- Address
- lock Available on a paid plan
Neoplasms (Oncology)
The Grand Hopital De Charleroi conducts extensive research on solid tumors and hematologic malignancies, aiming to evaluate new therapeutic agents and improve patient survival.
- Targeted therapies for HER2‑positive and HER2‑low breast cancer
- Immunotherapy combinations for non‑small cell lung cancer
- Novel antibody‑drug conjugates in advanced ovarian and pancreatic cancers
- Precision medicine approaches for colorectal and gastric cancers
With 156 active trials and 54 investigators, the site is a leading hub for oncology innovation in Belgium.
Hemic and Lymphatic Diseases (Hematology)
Clinical studies at the hospital focus on leukemia and lymphoma, testing cutting‑edge agents to enhance remission rates and quality of life.
- CAR‑T and bispecific antibodies for acute lymphoblastic leukemia
- Novel proteasome inhibitors in multiple myeloma maintenance
- Combination regimens for diffuse large B‑cell lymphoma in older adults
- Stem cell transplantation strategies for peripheral T‑cell lymphoma
The department’s expertise supports a broad portfolio of hematologic trials, reflecting the site’s commitment to blood‑cancer research.
Cardiovascular Diseases
Researchers investigate innovative approaches to reduce cardiovascular risk, especially in patients with established atherosclerotic disease.
- RNA‑based therapies to lower lipoprotein(a) levels
- Small‑molecule inhibitors targeting inflammatory pathways
- Long‑acting agents for secondary prevention of myocardial infarction and stroke
The cardiovascular program leverages the site’s multidisciplinary team to advance preventive cardiology.
Respiratory Tract Diseases
The center runs trials aimed at improving outcomes for patients with lung cancer and other serious respiratory conditions.
- EGFR and ALK inhibitor combinations for advanced non‑small cell lung cancer
- Immunotherapy with checkpoint inhibitors in small cell lung cancer
- Radiation‑plus‑immunotherapy strategies for early‑stage NSCLC after surgery
These studies address both targeted and immune‑based treatments, reflecting a comprehensive lung‑cancer research agenda.
Digestive System Diseases
Clinical trials target gastrointestinal malignancies, evaluating novel agents to increase response rates and prolong survival.
- FGFR‑targeted therapies for gastric and gastroesophageal junction cancers
- PARP inhibitor combinations in BRCA‑mutated colorectal cancer
- Anti‑angiogenic agents for metastatic colorectal adenocarcinoma
- Adaptive radiation approaches for locally advanced rectal cancer
The site’s gastro‑oncology team collaborates closely with surgical and radiotherapy units to deliver integrated trial designs.
Skin and Connective Tissue Diseases
Research includes both inflammatory skin disorders and dermatologic manifestations of systemic disease, focusing on new biologic and small‑molecule therapies.
- IL‑17 and IL‑23 pathway inhibitors for atopic dermatitis
- Adjustable dosing studies of brodalumab in severe plaque psoriasis
- Targeted treatments for hidradenitis suppurativa
These trials aim to improve symptom control and long‑term skin health for diverse patient populations.
Infectious Diseases (Virus and Bacterial)
The hospital conducts investigations into therapies for chronic infections and opportunistic fungal diseases, seeking safer and more effective options.
- Antiviral strategies for chronic hepatitis B
- Novel antifungal agents against multidrug‑resistant molds
- Antibiotic stewardship trials for febrile neutropenia in hematology patients
By integrating infectious disease expertise with oncology care, the site addresses critical complications in immunocompromised patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 19 therapeutic areas and 15 of 252 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 248 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 44 by active trials.
- 1Pfizer Inc.7active
lock +43 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB20trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Grand Hopital De Charleroi
lock Showing 1 of 165 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 252 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 21 | Unknown | 2018-12-18 | 2026-04-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.